COPY

IN THE CLAIMS

Please add Claims 36-48:

--36. (New) A compound of the general formula (I):

$$R^{1}-(X)_{m}-A-CH-CH-N$$
 R^{5}
 R^{5}
 R^{4}
(I)

wherein

R¹ is aryl which may have one or more suitable substituent(s), heterocyclic group or cyclo(lower)alkyl,

R² is hydrogen or amino protective group,

R³ and R⁴ are independently hydrogen, halogen, hydroxy, amino, nitro, carboxy, protected carboxy, aryl, lower alkyl, hydroxy(lower)alkyl, amino(lower)alkyl, acylamino(lower)alkyl, lower alkylamino(lower)alkyl which may have one or more suitable substituent(s), mono or di-(lower)alkylamino, acylamino, acyl group, lower alkoxy, halo(lower)alkoxy, lower alkenyloxy, lower alkoxy(lower)alkoxy, aryloxy, cyclo(lower)alkyloxy, heterocyclicoxy, ar(lower)alkyloxy, acyloxy, lower alkylcarbamoyl(lower)alkoxy, heterocycliccarbamoyl(lower)alkoxy, heterocycliccarbamoyl(lower)alkoxy, heterocycliccarbamoyl(lower)alkoxy, heterocycliccarbamoyl(lower)alkoxy, arylcarbamoyl(lower)alkoxy which may have lower alkylcarbamoyl(lower)alkoxy, N-lower alkyl-heterocyclic(lower)alkylcarbamoyl(lower) alkoxy, N-lower alkyl-lower alkyl-lower alkylcarbamoyl(lower)alkoxy or N-lower alkyl-cyclo(lower)alkylcarbamoyl(lower)alkoxy,

COPY

R⁵ is hydrogen, lower alkyl, or aryl,

A is lower alkylene which may have one or more suitable substituent(s) or lower alkenylene,

X is O, S, SO, SO₂ or NH, and

m is an integer of 0 or 1,

or a salt thereof,

wherein when R¹ is naphthyl and R⁵ is H, then X is not O.

37. (New) The compound of claim 36, wherein

R¹ is phenyl which may have 1 or 2 suitable substituent(s) selected from the group consisting of hydroxy and lower alkylsulfonylamino,

R² is hydrogen,

R³ is lower alkylcarbamoyl(lower)alkoxy, heterocycliccarbamoyl(lower)alkoxy, heterocycliccarbonyl(lower)alkoxy, N-lower alkyl-lower alkylcarbamoyl(lower)alkoxy, hydroxy, lower alkoxy, protected carboxy, arylcarbamoyl(lower)alkoxy which may have lower alkoxy or di(lower)alkylamino, di-lower alkylsulfamoyloxy, N-lower alkylheterocyclic(lower)alkylcarbamoyl(lower) alkoxy, N-lower alkyl-lower alkylcarbamoyl(lower)alkoxy or N-lower alkyl-cyclo(lower)alkylcarbamoyl(lower)alkoxy,

R4 is hydrogen,

1

R⁵ is hydrogen,

A is lower alkylene,

X is O, and

m is an integer of 1.--

38. (New) The compound of claim 37, wherein

R¹ is phenyl which may have hydroxy and methylsulfonylamino,

COPY •

R³ is ethylcarbamoylmethoxy, indolylcarbamoylmethoxy, piperidinocarbonylmethoxy, N-methylbutylcarbamoylmethoxy, hydroxy, butylcarbamoylmethoxy, methoxy, methoxycarbonyl, ethoxy, dimethylsulfamoyloxy, tetrazolylcarbamoylmethoxy, N-methylpyridylethylcarbamoylmethoxy, methoxyphenylcarbamoylmethoxy, thiazolylcarbamoylmethoxy, dihydroindolylcarbonylmethoxy, N-ethylpropylcarbamoylmethoxy, N-methylbutylcarbamoylmethoxy, N-ethylbutylcarbamoylmethoxy, dimethylaminophenylcarbamoylmethoxy or N-methylcyclohexylcarbamoylmethoxy.

39. (New) A process for preparing a compound of claim 36, or a salt thereof, which comprises,

(i) reacting a compound (II) of the formula:

$$R^{1}$$
— $(X)_{m}$ — A — CH — C — R^{5} (II)

wherein R¹, R⁵, A, X and m are each as defined in claim 36, with a compound (III) of the formula:

$$R^2$$
 HN
 R^3
(III)

wherein R^2 , R^3 and R^4 are each as defined in claim 36, or a salt thereof, to give a compound (I) of the formula:

COPY

$$R^{1}-(X)_{m}-A-CH-CH-N$$
 R^{2}
 R^{5}
 R^{3}
 R^{4}

(I)

wherein R¹, R², R³, R⁴, R⁵, A, X and m are each as defined in claim 36, or a salt thereof, or

(ii) subjecting a compound (Ia) of the formula:

$$R^{1}-(X)_{m}-A-CH-CH-N$$
 R^{2}
 R^{5}
 R^{3}
(Ia)

wherein R1, R3, R4, R5, A, X and m are each as defined in claim 36, and

R_a² is amino protective group, or a salt thereof, to elimination reaction of the amino protective group, to give a compound (Ib) of the formula:

$$R^{1}-(X)_{m}-A-CH-CH-N$$
 R^{5}
 R^{3}

(Ib)

wherein R¹, R³, R⁴, R⁵, A, X and m are each as defined in claim 36, or a salt thereof.

40. (New) A pharmaceutical composition which comprises the compound of claim 36 or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier or excipient.

COPY •

- 41. (New) A method for making a pharmaceutical composition or a medicament comprising admixing the compound of claim 36 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier or excipient.
- 42. (New) A compound of claim 36 or a pharmaceutically acceptable salt thereof in the form of a tablet, pellet, troche, capsule, suppository, cream, ointment, aerosol, powder for insufflation, solution, emulsion, or suspension.
- 43. (New) A method for the prophylactic and/or the therapeutic treatment of pollakiuria or urinary incontinence which comprises administering an effective amount of a compound of claim 36 or a pharmaceutically acceptable salt thereof to a subject in need thereof.--
- 44. (New) A method for agonizing a β_3 adrenergic receptor comprising contacting said receptor with the compound of claim 36.
- 45. (New) A method for inducing gut-selective sympathomimetic activity comprising administering an effective amount of the compound of claim 36 to a subject in need thereof.
- 46. (New) A method for the prophylactic and/or the therapeutic treatment of a gastrointestinal disorder comprising administering an effective amount of the compound of claim 36 or a pharmaceutically acceptable salt thereof to a subject in need thereof.
- 47. (New) A method for the prophylactic and/or the therapeutic treatment of an ulcer or pancreatitis comprising administering an effective amount of the compound of claim 36 or a pharmaceutically acceptable salt thereof to a subject in need thereof.
- 48. (New) A method for inducing lypolysis comprising administering an effective amount of the compound of claim 36 or a pharmaceutically acceptable salt thereof to a subject in need thereof.----